MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that two new studies have shown a link between Xarelto and stomach bleeds and eye hemorrhaging. Johnson & Johnson's blood thinner has been linked to uncontrollable bleeding events in the past, and now, according to Drug Watch, new data has emerged that Xarelto increases the risk of stomach bleeding and eye hemorrhaging. While the two new studies are concerning, because these are two newfound side effects of the blood thinner, the main concern is still uncontrollable bleeding events that lead to death. It has yet to be determined if lawsuit claims will develop based on the new report. A similar blood thinner drug, Pradaxa, settled 4K claims involving uncontrollable bleeding events for approximately $160K per case.
According to court documents, there are currently more than 300 lawsuits filed over Xarelto in the federal litigation in Louisiana, with an additional approximate 160 cases as of now with similar claims pending in Pennsylvania's mass tort proceeding. Lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, include claims of serious health problems and even death as a result of uncontrollable bleeding events. There is no known antidote at this time, according to experts. The federal multidistrict litigation (MDL) is being overseen in the U.S. District Court in the Eastern District of Louisiana (In Re: Xarelto Products Liability Litigation, No. 2592).
Chris Janish, CEO of MTS, commented on the recent studies linking Xarelto to stomach bleeds and eye hemorrhaging, "Clearly this new report comes at a tough time for J&J's Xarelto blood thinning drug as they continue to fight hundreds of uncontrollable bleeding claims, which continue to rise monthly. The litigation is expected to be a lengthy one and could be a two pronged fight for J&J if additional claims arise based on the new data."